AR056042A1 - Inhibidores de la map quinasa p38 y metodos para utilizarla - Google Patents
Inhibidores de la map quinasa p38 y metodos para utilizarlaInfo
- Publication number
- AR056042A1 AR056042A1 ARP060103657A ARP060103657A AR056042A1 AR 056042 A1 AR056042 A1 AR 056042A1 AR P060103657 A ARP060103657 A AR P060103657A AR P060103657 A ARP060103657 A AR P060103657A AR 056042 A1 AR056042 A1 AR 056042A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- heteroalkyl
- heterocyclyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
Abstract
Reivindicacion 1: Un compuesto con las formulas (1) o (2), o una sal farmacéuticamente aceptable del mismo, en el que: R1 es arilo or heteroarilo; R2 es -NRiRa, -NRiSO2Ra, -NRiC(=O)Ra, alquilsulfonamidilC1-6-alquiloC1-6, alcoxicarbonilaminoC1-6- alquiloC1-6, alquilo C3-6 lineal, alquenilo Cl 6, cicloalquilC3-7-alquiloC1-4, cicloalquenilo C3-7, cicloalquenilC3-7-alquiloC1-4, halo-alquiloC1-6, halocicloalquilo C3-7, hidroxialquilo C1-6, alquilsulfonilC1-6-alquiloC1-6, alquilsulfanilC1-6- alquiloC1-6, arilalquilo C1-6 o heteroarilalquilo C1-6; en el que: Ra es hidrogeno, alquilo C1-6, cicloalquilo C3-7, cicloalquilC3-7-alquiloC1-4, cicloalquenilo C3-7, cicloalquenilC3-7-alquiloC1-4, haloalquilo C1-6, halocicloalquilo C3-7, hidroxialquilo C1-6, alquilosulfonilC1-6-alquiloC1-6, alquilsulfanilC1-6-alquiloC1-6, arilsulfonilalquilo C1-6, arilo, arilalquilo C1-6, arilalquiloxi C1-6, heteroarilo, heteroarilalquilo C1-6, alquilsulfonamidilC1-6-alquiloC1-6, alcoxicarbonilaminoC1-6-alquiloC1-6, alcoxicarbonilC1-6-alquiloC1-6, alcoxiaminocarbonilC1-6-alquiloC1-6, aminocarbonilalquilo C1-6, alquilaminocarnonilC1-6-alquiloC1-6, carboxialquilo C1-6, heterociclilo, heterociclilalquilo, alquilcarbonilC1-6- alquiloC1-6, heterociclilalquilo C1-6, aminoalquilo C1-6, N-alquilaminoC1-6-alquiloC1-6, N,N-dialquilaminoC1-6-alquiloC1-6, alcoxiC1-6-alquiloC1-6, o heteroarilalquilo C1-6, y Ri es hidrogeno, hidroxi, o alquilo; R3 es hidrogeno o alquilo C1-6; R4 es hidrogeno, alquilo C1-6, hidroxi, amino, heteroalquilo C1-6, heteroalcoxi C1-6, heteroalquilamino C1-6, heterociclilo, heterociclilalquilo C1-6, hidroxicicloalquilo C3-6, cicloalquilC3-6-alquiloC1-6, alquilsulfonilo C1-6, alquilsulfonamido C1-6, arilo, heteroarilo, ariloalquilo C1-6, heteroarilalquilo C1-6, alcoxi C1-6, heteroarilalcoxi C1-6, -(CHRb)r-C(=O)-Rc, -(CHRb)r-O-C(=O)Rc, -(CHRb)r-NH-C(=O)Rc o -SO2-Rc; en el que: Rb es hidrogeno, alquilo C1-6 o heteroalquilo C1-6; Rc es alquilo C1- 6, hidroxi, amino, heteroalquilo C1-6, arilo, arilalquilo C1-6, heteroarilo, o heterociclilo; r es de 0 a 4; X y Y son nitrogeno, o uno de X y Y es nitrogeno y el es CRd; en el que: Rd es hidrogeno, alquilo C1-6, hidroxi, alcoxi C1-6, amino, haloalquilo C1-6, ciano, halo, heteroalquilo C1-6, C(=O)Re o -SO2-Re; en el que Re es hidrogeno o alquilo; W es un enlace, O, S(O)m, CH2 o NRf; en el que: m es de 0 a 2, y Rf es hidrogeno, alquilo C1-6, heteroalquilo C1-6, heterociclilo, hidroxicicloalquilo C3-6, -C(=O)-Rg o -SO2-Rg, en el que Rg es alquilo C1-6, arilo, arilalquilo C1-6, heteroarilo, heteroalquilo C1-6 o heterociclilo; o R4 y Rf junto con los átomos a los que están unidos pueden formar un anillo heterocíclico; A es O, CH2, S(O)n, C(=O), NRh, o CH(ORh), en el que: n es de 0 a 2; y Rh es hidrogeno o alquilo C1-6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71200905P | 2005-08-25 | 2005-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056042A1 true AR056042A1 (es) | 2007-09-12 |
Family
ID=37651018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103657A AR056042A1 (es) | 2005-08-25 | 2006-08-23 | Inhibidores de la map quinasa p38 y metodos para utilizarla |
Country Status (16)
Country | Link |
---|---|
US (1) | US7601726B2 (es) |
EP (1) | EP1919913A2 (es) |
JP (1) | JP2009506006A (es) |
KR (1) | KR101011957B1 (es) |
CN (1) | CN101243090A (es) |
AR (1) | AR056042A1 (es) |
AU (1) | AU2006283940A1 (es) |
BR (1) | BRPI0614884A2 (es) |
CA (1) | CA2620254A1 (es) |
IL (1) | IL189264A0 (es) |
MX (1) | MX2008002385A (es) |
NO (1) | NO20080675L (es) |
RU (1) | RU2008110941A (es) |
TW (1) | TW200740815A (es) |
WO (1) | WO2007023110A2 (es) |
ZA (1) | ZA200801441B (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9512125B2 (en) * | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
CA2647391C (en) * | 2006-04-04 | 2015-12-29 | The Regents Of The University Of California | Kinase antagonists |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) * | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
CN102124009B (zh) | 2008-07-08 | 2014-07-23 | 因特利凯公司 | 激酶抑制剂及其使用方法 |
WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
WO2010045542A2 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
IN2012DN01961A (es) | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
AR081377A1 (es) | 2010-05-10 | 2012-08-29 | Gilead Sciences Inc | Compuestos de pirazolopiridina bifuncionales |
EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
GB201009731D0 (en) * | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
CN105001165B (zh) * | 2011-04-22 | 2020-06-23 | 西格诺药品有限公司 | 取代的二氨基嘧啶其组合物,和用其治疗的方法 |
CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
JP6027611B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
AU2012302197B2 (en) | 2011-08-29 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN104470931B (zh) | 2012-05-21 | 2016-10-26 | 拜耳医药股份有限公司 | 取代的苯并噻吩并嘧啶 |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
EP2689779A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
AU2013323426A1 (en) | 2012-09-26 | 2015-04-23 | The Regents Of The University Of California | Modulation of ire1 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP6466924B2 (ja) | 2013-10-04 | 2019-02-06 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
DK3119397T3 (da) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
DE102015012050A1 (de) * | 2015-09-15 | 2017-03-16 | Merck Patent Gmbh | Verbindungen als ASIC-Inhibitoren und deren Verwendungen |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA3028718A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
AR109596A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos pirazolopiridina y sus usos |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
MD3755703T2 (ro) | 2018-02-20 | 2022-10-31 | Incyte Corp | Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US20220259199A1 (en) * | 2018-05-02 | 2022-08-18 | Jw Pharmaceutical Corporation | Novel heterocycle derivative |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
TW202028207A (zh) | 2018-09-25 | 2020-08-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2232038A1 (de) * | 1972-06-30 | 1974-01-10 | Hoechst Ag | 3-amino-1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine, ihre herstellung und verwendung |
US5656629A (en) * | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
GB0100621D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VI |
EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | INHIBITORS OF RHO KINASE |
CZ2004359A3 (cs) | 2001-09-26 | 2004-09-15 | Pharmacia Italia S.P.A. | Aminoindazolové deriváty aktivní jako inhibitory kinázy, způsob jejich přípravy a farmaceutické prostředky obsahující tyto deriváty |
TW200400034A (en) * | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
WO2004076450A1 (en) * | 2003-02-27 | 2004-09-10 | J. Uriach Y Compañia S.A. | Pyrazolopyridine derivates |
WO2004078116A2 (en) * | 2003-03-03 | 2004-09-16 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
SE0301906D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
US20050070542A1 (en) | 2003-09-03 | 2005-03-31 | Hodgetts Kevin J. | 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
CN1878773A (zh) | 2003-09-05 | 2006-12-13 | 神经能质公司 | 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶 |
WO2005063766A2 (en) | 2003-12-23 | 2005-07-14 | Novartis Ag | Bicyclic heterocyclic p-38 kinase inhibitors |
-
2006
- 2006-08-16 AU AU2006283940A patent/AU2006283940A1/en not_active Abandoned
- 2006-08-16 KR KR1020087004137A patent/KR101011957B1/ko not_active IP Right Cessation
- 2006-08-16 EP EP06778249A patent/EP1919913A2/en not_active Withdrawn
- 2006-08-16 WO PCT/EP2006/065329 patent/WO2007023110A2/en active Application Filing
- 2006-08-16 MX MX2008002385A patent/MX2008002385A/es active IP Right Grant
- 2006-08-16 JP JP2008527437A patent/JP2009506006A/ja active Pending
- 2006-08-16 CA CA002620254A patent/CA2620254A1/en not_active Abandoned
- 2006-08-16 BR BRPI0614884-0A patent/BRPI0614884A2/pt not_active IP Right Cessation
- 2006-08-16 RU RU2008110941/04A patent/RU2008110941A/ru not_active Application Discontinuation
- 2006-08-16 CN CNA2006800305906A patent/CN101243090A/zh active Pending
- 2006-08-22 TW TW095130751A patent/TW200740815A/zh unknown
- 2006-08-23 US US11/509,240 patent/US7601726B2/en not_active Expired - Fee Related
- 2006-08-23 AR ARP060103657A patent/AR056042A1/es unknown
-
2008
- 2008-02-04 IL IL189264A patent/IL189264A0/en unknown
- 2008-02-07 NO NO20080675A patent/NO20080675L/no not_active Application Discontinuation
- 2008-02-12 ZA ZA200801441A patent/ZA200801441B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2620254A1 (en) | 2007-03-01 |
IL189264A0 (en) | 2008-08-07 |
ZA200801441B (en) | 2009-09-30 |
MX2008002385A (es) | 2008-03-18 |
RU2008110941A (ru) | 2009-09-27 |
WO2007023110A2 (en) | 2007-03-01 |
WO2007023110A3 (en) | 2007-05-03 |
AU2006283940A1 (en) | 2007-03-01 |
NO20080675L (no) | 2008-03-13 |
CN101243090A (zh) | 2008-08-13 |
US7601726B2 (en) | 2009-10-13 |
BRPI0614884A2 (pt) | 2011-04-19 |
EP1919913A2 (en) | 2008-05-14 |
KR20080040726A (ko) | 2008-05-08 |
TW200740815A (en) | 2007-11-01 |
JP2009506006A (ja) | 2009-02-12 |
KR101011957B1 (ko) | 2011-01-31 |
US20070054915A1 (en) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056042A1 (es) | Inhibidores de la map quinasa p38 y metodos para utilizarla | |
DK2068921T3 (da) | Antistof-antagonister med høj affinitet af interleukin-13-receptor alpha 1 | |
CL2011002377A1 (es) | Compuestos derivados de heterociclos triciclicos fusionados de anillo antraceno y bifenileno, inhibidores de proteína ns5a del virus de hepatitis c (vhc); composicion farmaceutica que los comprende; y uso del compuesto en la preparacion de un medicamento util en el tratamiento de hepatitis c. | |
AR064736A1 (es) | Agonistas de gpcr | |
AR054688A1 (es) | Alquil-piridinas como inhibidores 11-beta de la diabetes | |
AR070493A1 (es) | Derivados heterociclicos de urea, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones bacterianas. | |
CO6180507A2 (es) | Derivado de 2-piridincarboxamida que tiene efecto activador de gk | |
AR061341A1 (es) | Compuesto de 5-amino-n-[(disustituido-fenil)carbonil-(amino-trifluoro-2-hidroxipropil)-fuorofenil]-1h-pirazol-4-carboxanmida, su uso para la preparacion de un medicamento composicion farmaceutica que lo comprende, proceso y compuestos intermediarios para su preparacion | |
UY29016A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
FR2885904B1 (fr) | Nouveaux derives du fluorene, compositions les contenant et utilisation | |
DE60309342D1 (de) | Benzimidazole und benzothiazole als inhibitoren der map-kinase | |
RS53420B (en) | MACROCYCLIC COMPOUNDS OF HINOXALINE, WHICH IS AN INHIBITOR OF HCV NS3 PROTEASES WITH OTHER HCV AGENTS | |
AR064735A1 (es) | Agonistas de gpcr y composicion farmaceutica en base al compuesto | |
CL2010000375A1 (es) | Compuestos mimeticos de glucocorticoides derivados de hidroxialquilo sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de un estado o trastorno seleccionado de diabetes tipo ii, obesidad, hipertension, entre otras (divisional de solicitud 585-03). | |
AR059445A1 (es) | Composiciones de antimicoticos ramnolipidicos y metodos de uso relacionados | |
DK1877379T3 (da) | Hydroxybenzamidderivater og anvendelse heraf som inhibitorer af hsp90 | |
PE20110286A1 (es) | Composiciones farmaceuticas que contienen vx-950 | |
CO5720212A1 (es) | Composicion de anticuerpo her2 | |
NO20073396L (no) | Farmasoytiske kombinasjoner av en angiotensinreceptorantagonist og en NEP-inhibitor | |
PA8565001A1 (es) | Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido | |
DE602006015642D1 (de) | Hcv-replikationshemmer | |
PA8607001A1 (es) | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 | |
PE20060934A1 (es) | Composicion farmaceutica que comprende un anticuerpo cd20 | |
DE602005011593D1 (de) | Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten | |
CO5680443A2 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |